financetom
Business
financetom
/
Business
/
Tempus AI Insider Sold Shares Worth $1,058,699, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tempus AI Insider Sold Shares Worth $1,058,699, According to a Recent SEC Filing
Mar 20, 2025 1:21 AM

03:59 AM EDT, 03/20/2025 (MT Newswires) -- James William Rogers, Chief Financial Officer, on March 18, 2025, sold 23,030 shares in Tempus AI ( TEM ) for $1,058,699. Following the Form 4 filing with the SEC, Rogers has control over a total of 164,750 Class A common shares of the company, with 164,750 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1717115/000141588925008658/xslF345X05/form4-03192025_060315.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Apple likely to release foldable iPhone as early as 2026, the Information reports
Apple likely to release foldable iPhone as early as 2026, the Information reports
Jul 23, 2024
July 23 (Reuters) - Apple ( AAPL ) is likely to introduce its foldable iPhone as early as 2026, the Information reported on Tuesday, that could mark the biggest hardware design revamp for the company's most popular product. The Cupertino, California-based company's plan to release a foldable iPhone could mimic a similar move by Samsung Electronics ( SSNLF ), which...
GSK Unit Says Dovato 'Non-Inferior' to Biktarvy in Phase 4 HIV Study
GSK Unit Says Dovato 'Non-Inferior' to Biktarvy in Phase 4 HIV Study
Jul 23, 2024
12:56 PM EDT, 07/23/2024 (MT Newswires) -- GSK (GSK) said Tuesday that its ViiV Healthcare subsidiary's phase 4 clinical trial showed that the two-drug regimen Dovato has non-inferior efficacy compared with the three-drug regimen Biktarvy in people living with human immunodeficiency virus-1, or HIV-1. The study compared Dovato, or dolutegravir and lamivudine, with the Biktarvy regimen, or bictegravir/emtricitabine/tenofovir alafenamide fumarate,...
Why Azitra Stock Is Moving Higher On Tuesday
Why Azitra Stock Is Moving Higher On Tuesday
Jul 23, 2024
Azitra, Inc. ( AZTR ) shares are trading higher after the company announced that the U.S. Patent and Trademark Office granted its patent application regarding the treatment of atopic dermatitis. The Details: The patent, U.S. Patent No. 12,036,248, protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis. The goal is to address diseases associated with a filaggrin deficiency,...
Apple likely to release foldable iPhone as early as 2026, the Information reports
Apple likely to release foldable iPhone as early as 2026, the Information reports
Jul 23, 2024
(Reuters) - Apple ( AAPL ) is likely to introduce its foldable iPhone as early as 2026, the Information reported on Tuesday, that could mark the biggest hardware design revamp for the company's most popular product. The Cupertino, California-based company's plan to release a foldable iPhone could mimic a similar move by Samsung Electronics ( SSNLF ), which pioneered the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved